Sulphonylureas are still prescribed in increasing amounts in the UK (Statistics and Research Division, DHSS, personal communication) despite the suggestion from the Universities Group Diabetic Program trial (1970) that their use may be associated with an increased risk of cardiovascular death. Tolbutamide, the first of the sulphonylureas still in common use, has a half-life of only five hours and is usually taken in two or three daily doses. The half-life of chlorpropamide, which is not metabolized by the liver, is 36 hours and its use/may lead to prolonged hypoglycaemia particularly in the elderly and those with renal impairment (Schen & Benaroya 1976) . Glibornuride has been widely used on the continent for several years, but only recently became available in the UK. This compound is rapidly absorbed from the gut and inactivated by the liver to give a half-life of eight hours. A trial was set up to examine the clinical acceptability of glibornuride and to confirm that like other sulphonylureas it leads to an increase in insulin secretion (Perkins et al. 1977) .
Methods
Twenty-six non-insulin-requiring diabetics were selected from the diabetic clinic; 20 were newly diagnosed (Group A) and 6 had previously been treated with chlorpropamide or tolbutamide (Group B). No patient had been treated with a biguanide. On entry to the trial the patients were examined fully and blood pressure was measured with a standard sphygmomanometer. Routine urinalysis (Clinitest, Ames) was carried out and capillary blood glucose was measured using Dextrostix and a reflectance meter (Ames). Blood was taken for haemoglobin, white count and differential, platelets, ESR and the following chemical analyses: liver function tests, calcium, phosphate, creatinine, uric acid, urea and electrolytes.
The patients were asked to make a 24-hour urine save (1 0 0 merthiolate) for measurement of creatinine and glucose excretion. A three-hour 100 g oral glucose tolerance test (OGTT) was performed after an overnight fast, with venous blood taken fasting and at hourly intervals for glucose (glucose oxidase method), serum insulin and growth hormone (Sonksen 1976) . A daily dose of glibornuride (12.5-50 mg) was prescribed, and in patients comprising Group B the other sulphonylurea was discontinued. Patients were asked to test their urine for glucose (Clinitest) three times daily and to record the result on a scale 0-5 (0 = negative, 5 =2%). The home urine test index (HUT) was calculated for each patient by dividing the total score by the number of tests made. Patients were recalled at two, four, eight and twelve weeks and questioned about suspected side-effects. Blood pressure and capillary blood glucose were measured and routine urinalysis performed. The results of home urine testing were recorded and glibornuride was prescribed, if necessary at an altered dose. At four, eight and twelve 1 Accepted21 March 1978 0141-0768/78 120899-05/S0I.OO/0 weeks measurements of 24-hour urinary creatinine and glucose and the initial blood measurements were repeated. At twelve weeks the trial was completed with an OGTT performed under identical conditions to the pre-treatment test. Four patients withdrew, leaving 16 patients in Group A and 6 in Group B.
Student's paired t test was used for statistical analysis. Correlation coefficients between plasma glucose, 24-hour urine glucose and home urine testing index were calculated using BMD program 02D (Biomedical Computer Programs 1971). Figure 1 . Mean blood glucose and serum insulin following 100 g oral glucose before (e) and after twelve weeks glibornuride (0) in 20 patients with no previous treatment (Group A) and 6 patients previously treated with another sulphonylurea (Group B). Vertical columns represent mean glucose and insulin areas of first and second glucose tolerance tests. (Blood glucose I mmol/l = 18. mg/dl) Glucose tolerance: Comparing OGTTs at the beginning and end of the study in Group A, there was a significant reduction (P<O.OOI) in fasting glucose from 11.7-7.0 mmoljl (211-126 mg/dl) and in each subsequent hourly sample (Figure 1 ). Fasting levels of immunoreactive insulin (IRI) were the same in both OGTTs but the insulin response to a glucose load was significantly greater after twelve weeks treatment with glibornuride ( Figure 1 ). In Group B, changing from another sulphonylurea to glibornuride was followed by a reduction in blood glucose at two and three hours, but this did not reach statistical significance (Figure 1 ). Accompanying this slight improvement in glucose tolerance, there was a fall in serum IRI in the second OGTT (Figure 1 ). This was significant (P < 0.05) at the three-hour sample.
Results
Post-prandial blood glucose (PPBG): In Group A there was a brisk reduction in PPBG at two weeks (P<0.005) with further falls in four and eight weeks (P <0.01 and P <0.05 respectively) ( Figure 2) . However, the twelve-week sample was obtained from the two-hour venous sample of the second OGrr and is thus not comparable with the previous post-prandial capillary samples. Group B had a small reduction in mean PPBG at two weeks (NS). Thereafter a gradual increase occurred in PPBG at four and eight weeks, which was not statistically significant. Again the twelve-week sample is not strictly comparable (Figure 2) .
24-IIour urine glucose:
In Group A, the mean 24-hour urine glucose excretion (UG) fell from 324 mmol (58 g) before treatment to 43.6 mmol (7.8 g) at four weeks (P<0.05). Further reductions to 17.8 mmol (3.2 g) at eight weeks and 15.8 mmol (2.8 g) at twelve weeks were not statistically significant (Figure 2 ). Mean UG in Group B fell after changing to glibornuride (not significant) and remained below 50 mmol (9 g) for the duration of the study. Figure 2 . Mean post-prandial blood glucose (± s.e.m.) and mean urine glucose excretion in Group A (A) and Group B (tI) over the twelve-week trial period. In some individuals twelve-week blood glucose was derived from two-hour glucose tolerance test data Home urine tests (HUT): These were not recorded before entry to the trial. In the first two weeks, mean HUT index in Group A was 1.21 and this fell to 0.79 by four weeks (P<0.05). Further falls were recorded at eight weeks (0.34) and twelve weeks (0.05) but these decrements were not statistically significant.
IIIdices ofdiabetic control: The relationship between PPBG, UG and home urine testing index before breakfast (HUTAM) and before supper (HUTPM) was examined and correlation coefficients calculated for all 22 subjects when the four values were recorded at comparable times (Table I) .
Toxicology: Plasma urate concentration in Group A increased steadily from 0.28 mmol/l (4.78 mg dl) on entry to 0.32 mmol/l (5.42 mg dl) at twelve weeks (P<O.05). The change in Serum glutamate-oxaloacetate transaminase (SGOT) increased dramatically in one patient who was withdrawn from the trial (see below), but no significant change was seen in the other substances measured throughout the study. There was no evidence of marrow suppression with Hb, WBC and platelets remaining normal.
Withdrawals: One patient left the country and another two were withdrawn because of suspected side-effects of abdominal pain and dizziness. However, both these symptoms had been recorded in the hospital notes before entry to the trial. The fourth withdrawal merits closer attention. This was a 52-year-old West Indian female whose glycosuria was detected after a two-month history of numbness in the feet and night cramps. She did not drink alcohol. Examination revealed impaired vibration sense in both feet and absent ankle jerks. Fasting blood glucose was 23.5 mmol/l (423 mg/dl) and SGOT 85 iu/l (normal 25-65 iu/l). Despite increasing doses of glibornuride up to 100 mg, hyperglycaemia persisted over the next ten days. SGOT was now 105 iu/l with the remaining liver function tests normal and glibornuride was replaced by two daily injections of Rapitard insulin. Good diabetic control was soon achieved but SGOT continued to rise to 650 iu/I and alkaline phosphatase to 57 KAU/IOO ml (normal 4-13 KAUjlOO ml). The bilirubin concentration remained normal and Australia antigen was negative. Liver biopsy was not performed. Over the next two months, her neurological symptoms improved and all liver function tests returned to normal.
Dose:
The mean daily dose of glibornuride was 35.8 mg at the onset and 50.0 mg at the end of the trial.
Discussion
Previous clinical trials from the continent (Biickert & Schweda 1971 , Schoffling et al. 1973 ) and UK (Logie & Stowers 1975) have shown glibornuride to be an effective oral hypoglycaemic agent with no serious reported side effects. We have also found glibornuride to be a welltolerated sulphonylurea. The one case described with abnormal liver function tests seems most likely to have experienced an episode of anicteric hepatitis coincident with glibornuride therapy. The small but significant rise in plasma urate concentration has not previously been reported with any sulphonylurea. Indeed glibornuride has been prescribed in gouty diabetics with no change in serum uric acid levels (Le Devehat & Lemoine 1974 , Mantel 1974 . Sulphonylureas are chemically related to thiazides which have a well-recognized hyperuricaemic effect. The mechanisms are complex but may be explained by competition for renal secretory transport (Goodman & Gilman 1970) . Glibornuride could have a similar action, although since urate excretion' was not monitored, a dietary explanation cannot be excluded.
The lack of correlation between PPBG and UG highlights the difficulty of assessing diabetic control. As might be expected home urine tests showed a close correlation with 24-hour urine glucose and it was immaterial whether the test was done in the morning or evening (r=0.99). However, all measurements of urine glucose are affected by the renal threshold for glucose, and post-prandial blood glucose is probably a better index of diabetic control in patients on a sulphonylurea.
The OGTTs confirm that glibornuride acts like other sulphonylureas by increasing the plasma insulin response to a glucose load. This is a useful and well-tolerated hypoglycaemic agent.
Summary
Twenty-six diabetic patients (20 untreated, Group A; and 6 previously receiving another sulphonylurea, Group B) were treated with glibornuride 12.5 mg to 100 mg daily for twelve weeks. Oral glucose tolerance tests performed before and at the end of the twelve-week period showed a significant increase in serum insulin concentrations and reduction in blood glucose in Group A, but no significant change in Group B. Diabetic control was monitored by blood glucose, 24-hour urine glucose and home urine tests for glycosuria. Mean serum uric acid concentration increased from 0.28 mmoll (4.7 mg/dl) to 0.32 mmol/l (5.42 mg/dl) in Group A.
No other biochemical or haematological changes were detected and the drug was well tolerated.
